Alumis reported that envudeucitinib, its selective oral TYK2 inhibitor, met primary and key secondary endpoints in two Phase 3 psoriasis trials and said it will seek regulatory approval later this year. The program produced high skin‑clearance rates across both ONWARD trials, with consistent placebo‑adjusted efficacy and durable responses through primary assessment windows. Markets reacted strongly: Alumis shares more than doubled on the topline readouts. Management positioned envudeucitinib as a potential oral competitor to existing TYK2 agents such as Sotyktu, noting the drug’s selectivity profile. The company will prepare a U.S. submission, citing statistically robust PASI and sPGA results across the registrational studies.